Loading stock data…
BBNX
$10.29+0.09 (+0.88%)
Market ClosedLast close May 1
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Beta Bionics, Inc. in the Healthcare sector is trading at $10.29. The stock is currently near its 52-week low of $8.80, remaining 46.3% below its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why BBNX maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.29
Potential Upside
5%
Whystock Fair Value$10.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$20.27+97.0%
Range$14.00 – $32.00
Fundamentals
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$504.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.51%
Volume
Today's trading volume
463,645
Recent News
Beta Bionics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Beta Bionics, Inc.'s Q1 2026 earnings call
Beta Bionics Inc (BBNX) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Operational ...
Beta Bionics Inc (BBNX) reports a 57% increase in net sales and raises full-year guidance despite facing FDA challenges and competitive pressures.
Beta Bionics Q1 Earnings Call Highlights
Beta Bionics (NASDAQ:BBNX) reported first-quarter 2026 net sales of $27.6 million, up 57% year-over-year, as management cited growth in new patient starts, a rising base of recurring pharmacy users, and continued expansion of pharmacy channel access for its iLet insulin delivery system. Quarterly r
Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates
Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +8.24% and -0.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Beta Bionics, Inc. (BBNX) Soars 10.3%: Is Further Upside Left in the Stock?
Beta Bionics, Inc. (BBNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.